Abstract 1790P
Background
Following several practice changing clinical trials regarding management of mHSPC, international guidelines now recommend ‘treatment intensification’ of ADT in combination with either docetaxel and/or novel hormonal therapy (NHT). The national utilisation of these treatments in England, UK and the determinants of variation are yet to be explored.
Methods
This national population based study using data from the National Prostate Cancer Audit (NPCA) identified all patients newly diagnosed with mHSPC in the English National Health Service (NHS) between 2018 and 2021. Patients receiving docetaxel, enzalutamide, abiraterone or apalutamide within 6 months of diagnosis were identified in the Systemic Anti-Cancer Dataset (SACT). Treatment patterns were studied in the overall population and also by age, ethnicity, deprivation and co-morbidity.
Results
Of the 13,820 men diagnosed with mHSPC in England between 2018 and 2021, 5,346 (38.7%) received ‘treatment intensification’ with either docetaxel, enzalutamide, abiraterone or apalutamide. Of these, 3,386 (24.5%) received docetaxel, 1,736 (12.6%) enzalutamide, 167 (1.2%) Abiraterone and 57 (0.4%) apalutamide. Utilisation of docetaxel peaked in 2018 and utilisation of enzalutamide has steadily increased (0.2% 2018 to 28.3% 2020). Abiraterone and Apalutamide utilisation have also increased during the study period (Table). Patients who were younger or who lived in least deprived areas or who had fewer co-morbidities were more likely to receive treatment intensification. There was no evidence of variation in utilisation according to patient ethnicity.
Table: 1790P
Percentage utilisation of treatment intensification for mHSPC over time
2018 | 2019 | 2020 | 2021 | |
Any treatment intensification | 38.1% | 38.3% | 42.0% | 36.7% |
Docetaxel | 37.6% | 37.3% | 11.6% | 11.2% |
Enzalutamide | 0.2% | 0.7% | 28.3% | 21.8% |
Abiraterone | 0.3% | 0.3% | 2.1% | 2.1% |
Apalutamide | 0% | 0% | 0% | 1.6% |
Conclusions
This study identifies the underutilisation of treatment intensification for mHSPC in England, particularly amongst certain patient groups. Further studies are needed to understand the reasons for underutilisation of intensified treatments in this setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1794P - Prognostic role of metastatic site in patients with de novo metastatic prostate cancer: A population-based analysis in new hormonal agents era
Presenter: Emre Yekeduz
Session: Poster session 14
1795P - China ARCHES: A multicenter phase III randomized double-blind placebo (PBO)-controlled efficacy and safety trial of enzalutamide (ENZA) + androgen deprivation therapy (ADT) vs PBO + ADT in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Gongqian Zeng
Session: Poster session 14
1796P - Real-world analysis of metastatic hormone-sensitive prostate cancer: Are randomized clinical trials more trustworthy? Insights from PIONEER, the European network of excellence for big data in prostate cancer
Presenter: Juan Gómez Rivas
Session: Poster session 14
1797P - Application of novel machine learning model in [68Ga] Ga-PSMA-11 PET/CT: Predicting survival in oligometastatic prostate cancer patients
Presenter: Mikaela Dell'Oro
Session: Poster session 14
1800P - Differential tumor gene-expression profiling of patients (pts) with de-novo metastatic castration-sensitive prostate cancer (dn-mCSPC) versus (vs.) mCSPC relapsing after prior localized therapy (PLT-mCSPC)
Presenter: Vinay Mathew Thomas
Session: Poster session 14
1803P - Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with <italic>AR</italic> ligand-binding domain (LBD) mutations
Presenter: Daniel Petrylak
Session: Poster session 14